PATRICK DISPOTO: Open Payments
NPI 1659815710 · CLIFTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,911 in 141 payments from 14 companies in 2025. Trend: 2023 $962 · 2024 $1,686 · 2025 $1,911
Food & beverage: $1,911
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 14 | $270 |
| Neurocrine BioSciences, Inc. | 19 | $267 |
| Otsuka America Pharmaceutical, Inc. | 15 | $212 |
| Vanda Pharmaceuticals Inc. | 11 | $207 |
| E.R. Squibb & Sons, L.L.C. | 13 | $178 |
| ABBVIE INC. | 32 | $153 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $135 |
| Teva Pharmaceuticals USA, Inc. | 8 | $135 |
| Janssen Pharmaceuticals, Inc | 6 | $105 |
| Supernus Pharmaceuticals, Inc. | 5 | $77 |
Products named: INGREZZA, REXULTI, ARISTADA, COBENFY, VRAYLAR, FANAPT, CAPLYTA, INVEGA SUSTENNA.
Industry payments across NJ — which companies pay providers there.
